Pathophysiological premises to radiotracers for bone metastases.

Area of Science:

• Nuclear Medicine
• Oncology
• Radiochemistry

Background:

• Bone metastases are a significant complication of various cancers.
• Accurate detection and characterization of bone metastases are crucial for treatment planning and patient management.
• Radiopharmaceuticals play a vital role in the diagnostic imaging of bone metastases.

Purpose of the Study:

• To review important radiocompounds for detecting and characterizing bone metastases.
• To categorize radiotracers based on their targeting mechanisms (osteotropic vs. oncotropic).
• To discuss the clinical utility and potential future applications of these agents.

Main Methods:

• Systematic review of literature on radiopharmaceuticals for bone metastasis imaging.
• Categorization of agents into osteotropic (bone-seeking) and oncotropic (tumor-seeking) radiotracers.
• Discussion of uptake mechanisms, pharmacokinetics, and clinical applications.

Main Results:

• Technetium-99m diphosphonates are widely used osteotropic agents for visualizing bone reactions.
• Various oncotropic agents, including F-18 fluoride, radiolabeled somatostatin analogues, and F-18 fluorodeoxyglucose, are effective for detecting tumor cells.
• The review details the properties and applications of specific agents like Tc-99m sestamibi, F-18 choline, and F-18 thymidine.

Conclusions:

• Radiocompounds are essential tools for the diagnosis and characterization of bone metastases.
• The choice of radiotracer depends on whether the focus is on bone reaction or direct tumor detection.
• Diagnostic radiotracers also hold potential for patient recruitment in radionuclide therapy and dosimetric evaluation.